Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,022.40 | 1.20 | -0.01% |
| CAC 40 | 8,158.06 | 46.04 | 0.57% |
| DAX 40 | 24,490.41 | 139.29 | 0.57% |
| Dow JONES (US) | 48,354.50 | 107.43 | -0.22% |
| FTSE 100 | 9,929.54 | 63.01 | 0.64% |
| HKSE | 25,854.60 | 219.37 | 0.86% |
| NASDAQ | 23,439.73 | 34.62 | -0.15% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.13 | 22.14 | 0.16% |
| S&P 500 | 6,897.92 | 7.82 | -0.11% |
| S&P/ASX 200 | 8,717.10 | 4.10 | -0.05% |
| SSE Composite Index | 3,965.12 | 0.16 | -0.00% |